Skip to main content
main-content
Top

18-12-2020 | Upadacitinib | News

approvalsWatch

EMA gives nod to upadacitinib for psoriatic arthritis, ankylosing spondylitis

Author: Claire Barnard

share
SHARE
print
PRINT
insite
SEARCH

medwireNews: The EMA’s Committee for Medicinal Products for Human Use has recommended that the indication for upadacitinib should be expanded to include psoriatic arthritis (PsA) and ankylosing spondylitis (AS).

Previously approved for rheumatoid arthritis, the Janus kinase (JAK) inhibitor is now indicated for the treatment of active PsA, either as monotherapy or in combination with methotrexate, in adult patients with an inadequate response or intolerance to one or more DMARDs. Upadacitinib may also be given to adult patients with AS and an inadequate response to conventional therapy.

The clinical benefits of upadacitinib in PsA were demonstrated in the phase 3 SELECT-PsA-1 and SELECT-PsA-2 trials, involving patients with and without prior exposure to biologics, while the phase 2/3 SELECT-AXIS 1 trial showed that the JAK inhibitor improves outcomes for patients with AS and previous exposure to nonsteroidal anti-inflammatory drugs.

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2020 Springer Healthcare Ltd, part of the Springer Nature Group

share
SHARE
print
PRINT

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

Rituximab and rheumatology practice in the COVID-19 era

How can rheumatologists respond to the challenges associated with rituximab use during the pandemic?